Acromegaly: Pathology, diagnosis and treatment

Acromegaly: Pathology, Diagnosis and Treatment

Volumn , Issue , 2005, Pages 1-153

  van der Lely, Aart Jan ^a   Beckers, Albert ^b   Daly, Adrian F ^b   Lamberts, Steven W J ^a   Clemmons, David R ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29344472317     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (441)

1. Starling EH. The Croonian Lectures on the chemical correlation of the functions of the body. Lecture I: The chemical control of the functions of the body. Lancet 1905; 2:339-341.
2. Sheaves R. A history of acromegaly. Pituitary 1999; 2:7-28.
3. Hosovski E. A case of acromegaly in the Middle Ages. Anthropol Anz 1991; 49(3):273-279.
4. Andolz Canela R. Fermin Arrudi. In: El Gigante Aragonés. Zaragoza: Mira Editores S.A., 1998.
5. Marie P, De Souza-Leite JD. Essays on Acromegaly. London: New Sydenham Society, 1891.
6. Verga A. Caso singolare di prosopectasia. Rend R 1 Limbardo Classe Sc Med Nat 1864; 1:111-117.
7. Brigidi V. Studii anatomo-patologici sopra un uomo divenuto stranamente deforme per cronica infermita. Arch Scuola Anat Patol Firenze 1881; 65-92.
8. Brunori A, Bruni P, Delitalia A, Chiapetta F. Acromegaly and pituitary tumors: early anatomoclinical observations. Surg Neurol 1995; 44:83-87.
9. Fritsche CF, Klebs TAE. Ein Beitrag zur Pathologie des Riesenwuchs. In: Klinische und pathologischananatomische Untersuchungen. Leipzig: Vogel, 1884.
10. Marie P. Sur deux cas d’acromegalie: hypertrophie singulére non congenitale des extrémitiés supérieures, inférieures et céphalique. Rev Med 1886; 6:297-333.
11. Minkowski O. Über einen Fall von Akromegalie. Berl Klin Wochensch 1887; 21:371-374.
12. Massalongo R. Sull’acromegalia. Rif Med 1892; 8:74-77.
13. Benda C. Beiträge zur normalen und pathologischen Histologie der menschlichen Hypophysis Cerebri. Klin Wochenschr 1900; 36:1205.
14. Vassale G, Sacchi E. Sulla distruzione della ghiandola pituitaria: richerche sperimentali. Riv Sper Freniatr Med Leg 1892; 18:525-561.
15. Vassale G, Sacchi E. Ulteriori esperienze sulla ghiandola pituitaria. Riv Sper Freniatr Med Leg 1894; 20:83-88.
16. Paulesco NC. L’hypophyse du cerveau. J Physiol Pathol Gen 1907; 9: 441-456.
17. Aschner B. Über die Funktion der Hypophyse. Pflügers Arch Physiol 1912; 146:1.
18. Cushing HW. The hypophysis cerebri: clinical aspects of hyperpituitarism and hypopituitarism. J Am Med Assoc 1909; 53:250-255.
19. Medvei VC. The History of Clinical Endocrinology. London: Parthenon, 1993.
20. Caton R, Paul FT. Notes of a case of acromegaly treated by operation. Br Med J 1893; 2:1421-1423.
21. Couldwell WT. Transsphenoidal and transcranial surgery for pituitary adenomas. J Neuro-Oncol 2004; 69:237-256.
22. Schloffer H. Erfolgreiche Operation eines Hypophysentumors auf nasalem Wege. Wien Klin Wochenschr 1907; 20:621-624.
23. Artico M, Pastore FS, Fraioli B, Giuffré R. The contributions of Davide Giordano (1864-1954) to pituitary surgery: the transglabellar-nasal approach. Neurosurgery 1998; 42:909-912.
24. Kocher T. Ein Fall von Hypophysis-tumor mit operativer Heilung. Dtsch Z Chir 1909; 100:13-37.
25. Cushing H. Partial hypophysectomy for acromegaly; with remarks on the function of the hypophysis. Ann Surg 1909; 50:1002-1017.
26. Liu JK, Das K, Weiss MH, Laws ER, Couldwell WT. The history and evolution of transsphenoidal surgery. J Neurosurg 2001; 95:1083-1096.
27. Lanzino G, Laws ER. Pioneers in the development of transsphenoidal surgery: Theodor Kocher, Oskar Hirsch, and Norman Dott. J Neurosurg 2001; 95:1097-1103.
28. Hardy J, Wigser SM. Trans-sphenoidal surgery of pituitary fossa tumors with televised radiofluoroscopic control. J Neurosurg 1965; 23:612-619.
29. Béclère A. Le traitment des tumeurs hypophysaires, du gigantisme et de l’acromegalie par la radio-thérapie. Bull Mem Soc Hȏp Paris 1909; 27:274.
30. Béclère A. The radio-therapeutic treatment of tumours of the hypophysis, gigantism and acromegaly. Arch Roentgen Radiol 1909; 14:147.
31. Gramagna A. Un cas d’acromegalie traité par la radiothérapie. Rev Neurol 1909; 17:15.
32. Evans HM, Long JA. The effect of the anterior lobe of the pituitary administered intra-peritoneally upon growth, maturity and oestrus cycle of the rat. Anat Rec 1921; 21:62.
33. Li CH, Evans HM, Simpson ME. Isolation and properties of hypophyseal growth hormone. J Biol Chem 1945; 159:353-366.
34. Wade N. The Nobel Duel. Garden City, NY: Anchor Press-Doubleday, 1981.
35. Trueta J. Studies of the Development and Decay of the Human Frame. London: William Heinemann, 1968.
36. Schally AV. Aspects of hypothalamic regulation of the pituitary gland with major emphasis on its implications for the control of reproductive processes. Nobel Lecture, December 1977.
37. Guillemin R. Peptides in the brain. The new endocrinology of the neuron. Nobel Lecture, December 1977.
38. Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49:825-836.
39. Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, Van Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature 1972; 235:107.
40. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301:1138-1142.
41. Froesch ER, Burgi H, Ramsier EB, Bally P, Labhart A. Antibody suppressible and nonsuppressible insulin-like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 1963; 42:1816-1834.
42. Klapper DG, Svoboda ME, Van Wyk JJ. Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor-I. Endocrinology 1983; 112:2215-2217.
43. Daughaday WH, Hall K, Salmon WD Jr, van den Brande JL, Van Wyk JJ. On the nomenclature of the somatomedins and insulin-like growth factors. J Clin Endocrinol Metab 1987; 65:1075-1076.
44. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis. Endocr Rev 2001; 22:53-74.
45. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968; 83:783-790.
46. Hellman B, Lernmark A. Inhibition of the in vitro secretion of insulin by an extract of pancreatic alpha-1 cells. Endocrinology 1969; 84:1484-1488.
47. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179:77-79.
48. Besser GM, Mortimer CH, Carr D, Schally AV, Coy DH, Evered D, Kastin AJ, Tunbridge WMG, Thorner MO, Hall R. Growth hormone release inhibiting hormone in acromegaly. Br Med J 1974; 1:352-355.
49. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31:1133-1140.
50. Wass JAH, Thorner MO, Morris DV, Rees LH, Mason SA, Jones AE, Besser GM. Long-term treatment of acromegaly with bromocriptine. Br Med J 1977; 1:875-878.
51. Owerbach D, Rutter WJ, Martial JA, Baxter JD, Shows TB. Genes for growth hormone, chorionic somatommammotropin, and growth hormone-like gene on chromosome 17 in humans. Science 1980; 209(4453):289-292.
52. Phillips, JA III, Cogan JD. Genetic basis of endocrine disease.
53. Molecular basis of familial human growth hormone deficiency. J Clin Endocrinol Metab 1994; 78(1):11-16.
54. Millar DS, Lewis MD, Horan M, Newsway V, Easter TE, Gregory JW, Fryklund L, Norin M, Crowne EC, Davies SJ, Edwards P, Kirk J, Waldron K, Smith PJ, Phillips JA III, Scanlon MF, Krawczak M, Cooper DN, Procter AM. Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature. Hum Mutat 2003; 21(4):424-440.
55. Masuda N, Watahiki M, Tanaka M, Yamakawa M, Shimizu K, Nagai J, Nakashima K. Molecular cloning of cDNA encoding 20 kDa variant human growth hormone and the alternative splicing mechanism. Biochim Biophys Acta 1988; 949(1):125-131.
56. Stolar MW, Baumann G, Vance ML, Thorner MO. Circulating growth hormone forms after stimulation of pituitary secretion with growth hormone- releasing factor in man. J Clin Endocrinol Metab 1984; 59(2):235-239.
57. Frankenne F, Rentier-Delrue F, Scippo ML, Martial J, Hennen G. Expression of the growth hormone variant gene in human placenta. J Clin Endocrinol Metab 1987; 64(3):635-637.
58. Beckers A, Stevenaert A, Foidart JM, Hennen G, Frankenne F. Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab 1990; 71(3):725-731.
59. Herrington J, Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab 2001; 12(6):252-257.
60. Mannor DA, Winer LM, Shaw MA, Baumann G. Plasma growth hormone (GH)-binding proteins: effect on GH binding to receptors and GH action. J Clin Endocrinol Metab 1991; 73(1):30-34.
61. Baumann G, Mercado M. Growth hormone-binding proteins in plasma. Nutrition 1993; 9(6):546-553.
62. Baumann G. Growth hormone binding protein. The soluble growth hormone receptor. Minerva Endocrinol 2002; 27(4):265-276.
63. Amit T, Youdim MB, Hochberg Z. Clinical review 112: Does serum growth hormone (GH) binding protein reflect human GH receptor function? J Clin Endocrinol Metab 2000; 85(3):927-932.
64. Barkan AL, Dimaraki EV, Jessup SK, Symons KV, Ermolenko M, Jaffe CA. Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. J Clin Endocrinol Metab 2003; 88(5):2180-2184.
65. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25(3):426-457.
66. Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, Ghigo E, Dieguez C, Casanueva FF. Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 2003; 88(7):3450-3453.
67. Smith PJ, Spurrell EL, Coakley J, Hinds CJ, Ross RJ, Krainer AR, Chew SL. An exonic splicing enhancer in human IGF-I pre-mRNA mediates recognition of alternative exon 5 by the serine-arginine protein splicing factor-2/alternative splicing factor. Endocrinology 2002; 143(1):146-154.
68. Rotwein P, Pollock KM, Didier DK, Krivi GG. Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J Biol Chem 1986; 261(11):4828-4832.
69. Rinderknecht E, Humbel RE. The amino acid sequence of human insulinlike growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253(8):2769-2776.
70. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14(3):699-704.
71. Skalkidou A, Petridou E, Papathom E, Salvanos H, Chrousos G, Trichopoulos D. Birth size and neonatal levels of major components of the IGF system: implications for later risk of cancer. J Pediatr Endocrinol Metab 2002; 15(9): 1479-1486.
72. Janssen JA, Lamberts SW. IGF-I and longevity. Horm Res 2004; 62(suppl 3): 104-109.
73. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL. Insulin-like growth factors and coronary heart disease. Cardiol Rev 2005; 13(1):35-39.
74. Russell SM, Spencer EM. Local injections of human or rat growth hormone or of purified human somatomedin-C stimulate unilateral tibial epiphyseal growth in hypophysectomized rats. Endocrinology 1985; 116(6):2563-2567.
75. Schoenle E, Zapf J, Hauri C, Steiner T, Froesch ER. Comparison of in vivo effects of insulin-like growth factors I and II and of growth hormone in hypophysectomized rats. Acta Endocrinol (Copenh) 1985; 108(2):167-174.
76. Zapf J, Schoenle E, Froesch ER. In vivo effects of the insulin-like growth factors (IGFs) in the hypophysectomized rat: comparison with human growth hormone and the possible role of the specific IGF carrier proteins. Ciba Found Symp 1985; 116:169-187.
77. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22(1):53-74.
78. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Physiol 1993; 55:131-153.
79. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995; 73(3):311-331.
80. Bondy CA, Cheng CM. Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 2004; 19:490(1-3):25-31
81. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF- 1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004; 24(3):435-444.
82. Fowden AL. The insulin-like growth factors and feto-placental growth. Placenta 2003; 24(8-9):803-812.
83. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23(6):824-854.
84. Edmondson SR, Thumiger SP, Werther GA, Wraight CJ. Epidermal homeostasis: the role of the growth hormone and insulin-like growth factor systems. Endocr Rev 2003; 24(6):737-764.
85. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999; 2(1):29-41.
86. Etxabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest 1993; 16(3):181-187.
87. Ritchie CM, Atkinson AB, Kennedy AL, Lyons AR, Gordon DS, Fannin T, Hadden DR. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J 1990; 59(1):55-62.
88. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988; 223(4):327-335.
89. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980; 12(1): 71-79.
90. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M., Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espan˜ ol de Acromegalia, REA). Eur J Endocrinol 2004; 151(4): 439-446.
91. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf) 1987; 26(4):481-512.
92. Bates AS, Van’t Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86(5):293-299.
93. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41(1):95-102.
94. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970; 39(153):1-16.
95. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83(10):3419-3426.
96. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003; 58(1):86-91.
97. Arita K, Kurisu K, Tominaga A, Eguchi K, Iida K, Uozumi T, Kasagi F. Mortality in 154 surgically treated patients with acromegaly-a 10-year follow-up survey. Endocr J 2003; 50(2):163-172.
98. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89(4):1613-1617.
99. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89(2):667-674.
100. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004; 89(6):2789-2796.
101. Asa SL, Kovacs K. Pituitary pathology in acromegaly. Endocrinol Metab Clin North Am 1992; 21(3):553-574.
102. Kovacs K, Horvath E, Vidal S. Classification of pituitary adenomas. J Neurooncol 2001; 54(2):121-127.
103. Horvath E, Kovacs K. Ultrastructural diagnosis of human pituitary adenomas. Microsc Res Tech 1992; 20(2):107-135.
104. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998; 19(6):798-827.
105. Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Sawano S, Takada K. Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 1993; 33(1):20-27.
106. Bando H, Sano T, Ohshima T, Zhang CY, Yamasaki R, Matsumoto K, Saito S. Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 1992; 39(4):355-363.
107. Ragel BT, Couldwell WT. Pituitary carcinoma: a review of the literature. Neurosurg Focus 2004; 16(4):E7.
108. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2002; 2(11):836-849.
109. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998; 83(5):1604-1610.
110. Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li CC, Hirokawa M, Kovacs K, Ezzat S. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 2004; 89(4):1904-1911.
111. Ezzat S, Zheng L, Asa SL. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 2004; 18(10):2543-2552.
112. Yu S, Asa SL, Weigel RJ, Ezzat S. Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. J Biol Chem 2003; 278(22):19597-19602.
113. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002; 109(1):69-78.
114. Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM. The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol 2003; 148(2):203-211.
115. McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA, Gittoes NJ. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) 2003; 58(2):141-150.
116. Thakker RV, Pook MA, Wooding C, Boscaro M, Scanarini M, Clayton RN. Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations. J Clin Invest 1993; 91(6):2815-2821.
117. Poncin J, Stevenaert A, Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur J Endocrinol 1999; 140(6):573-576.
118. Beckers A, Betea D, Socin HV, Stevenaert A. The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med 2003; 253(6): 599-605.
119. Agarwal SK, Lee BA, Sukhodolets KE, Kennedy PA, Obungu VH, Hickman AB, Mullendore ME, Whitten I, Skarulis MC, Simonds WF, Mateo C, Crabtree JS, Scacheri PC, Ji Y, Novotny EA, Garrett-Beal L, Ward JM, Libutti SK, Richard AH, Cerrato A, Parisi MJ, Santa A, Oliver B, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 2004; 1014:189-198.
120. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002; 87(2):457-465.
121. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985; 64(4):270-283.
122. Stratakis CA, Matyakhina L, Courkoutsakis N, Patronas N, Voutetakis A, Stergiopoulos S, Bossis I, Carney JA. Pathology and molecular genetics of the pituitary gland in patients with the’complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). Front Horm Res 2004; 32:253-264.
123. Sandrini F, Kirschner LS, Bei T, Farmakidis C, Yasufuku-Takano J, Takano K, Prezant TR, Marx SJ, Farrell WE, Clayton RN, Groussin L, Bertherat J, Stratakis CA. PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. J Med Genet 2002; 39(12):e78.
124. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT. Characterization of gsp-mediated growth hormone excess in the context of McCune- Albright syndrome. J Clin Endocrinol Metab 2002; 87(11):5104-5112.
125. Soares BS, Frohman LA. Isolated familial somatotropinoma. Pituitary 2004; 7(2):95-101.
126. Luccio-Camelo DC, Une KN, Ferreira RE, Khoo SK, Nickolov R, Bronstein MD, Vaisman M, Teh BT, Frohman LA, Mendonca BB, Gadelha MR. A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur J Endocrinol 2004; 150(5):643-648.
127. Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman RD, Frohman LA. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J Clin Endocrinol Metab 2000; 85(2):707-714.
128. Verloes A, Stevenaert A, Teh BT, Petrossians P, Beckers A. Familial acromegaly: case report and review of the literature. Pituitary 1999; 1(3-4):273-277.
129. Athanassiadi K, Exarchos D, Tsagarakis S, Bellenis I. Acromegaly caused by ectopic growth hormone-releasing hormone secretion by a carcinoid bronchial tumor: a rare entity. J Thorac Cardiovasc Surg 2004; 128(4): 631-632.
130. Boix E, Pico A, Pinedo R, Aranda I, Kovacs K. Ectopic growth hormonereleasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxf) 2002; 57(1):131-134.
131. Jansson JO, Svensson J, Bengtsson BA, Frohman LA, Ahlman H, Wangberg B, Nilsson O, Nilsson M. Acromegaly and Cushing’s syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: in vitro responses to GHRH and GHRP-6. Clin Endocrinol (Oxf) 1998; 48(2): 243-250.
132. Ezzat S, Ezrin C, Yamashita S, Melmed S. Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor. Cancer 1993; 71(1):66-70.
133. Melmed S, Ziel FH, Braunstein GD, Downs T, Frohman LA. Medical management of acromegaly due to ectopic production of growth hormonereleasing hormone by a carcinoid tumor. J Clin Endocrinol Metab 1988; 67(2):395-399.
134. Mitsuya K, Nakasu Y, Nioka H, Nakasu S. Ectopic growth hormone-releasing adenoma in the cavernous sinus-case report. Neurol Med Chir (Tokyo) 2004; 44(7):380-385.
135. Matsuno A, Katayama H, Okazaki R, Toriumi M, Tanaka H, Akashi M, Tanaka K, Murakami M, Tanaka H, Nagashima T. Ectopic pituitary adenoma in the sphenoid sinus causing acromegaly associated with empty sella. ANZ J Surg 2001; 71(8):495-498.
136. Gondim JA, Schops M, Ferreira E, Bulcao T, Mota JI, Silveira C. Acromegaly due to an ectopic pituitary adenoma in the sphenoid sinus. Acta Radiol 2004; 45(6):689-691.
137. Asa SL, Scheithauer BW, Bilbao JM, Horvath E, Ryan N, Kovacs K, Randall RV, Laws ER Jr, Singer W, Linfoot JA. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab 1984; 58(5):796-803.
138. Karges B, Pfaffle R, Boehm BO, Karges W. Acromegaly induced by growth hormone replacement therapy. Horm Res 2004; 61(4):165-169.
139. Smith DA, Perry PJ. The efficacy of ergogenic agents in athletic competition. Part II: Other performance-enhancing agents. Ann Pharmacother 1992; 26(5):653-659.
140. Macintyre JG. Growth hormone and athletes. Sports Med 1987; 4(2): 129-142.
141. Minuto F, Barreca A, Melioli G. Indirect evidence of hormone abuse. Proof of doping? J Endocrinol Invest 2003; 26(9):919-923.
142. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003; 26(12):1242-1247.
143. Vitale G, Pivonello R, Lombardi G, Colao A. Cardiovascular complications in acromegaly. Minerva Endocrinol 2004; 29(3):77-88.
144. Frustaci A, Chimenti C, Setoguchi M, Guerra S, Corsello S, Crea F, Leri A, Kajstura J, Anversa P, Maseri A. Cell death in acromegalic cardiomyopathy. Circulation 1999; 99(11):1426-1434.
145. Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 2003; 24(3):272-277.
146. Ozbey N, Oncul A, Bugra Z, Vural A, Erzengin F, Orhan Y, Buyukozturk K, Sencer E, Molvalilar S. Acromegalic cardiomyopathy: evaluation of the left ventricular diastolic function in the subclinical stage. J Endocrinol Invest 1997; 20(6):305-311.
147. Cuocolo A, Nicolai E, Fazio S, Pace L, Maurea S, Cittadini A, Sacca L, Salvatore M. Impaired left ventricular diastolic filling in patients with acromegaly: assessment with radionuclide angiography. J Nucl Med 1995; 36(2):196-201.
148. Bertoni PD, Morandi G. Impaired left ventricular diastolic function in acromegaly: an echocardiographic study. Acta Cardiol 1987; 42(1):1-10.
149. Bihan H, Espinosa C, Valdes-Socin H, Salenave S, Young J, Levasseur S, Assayag P, Beckers A, Chanson P. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 2004; 89(11):5308-5313.
150. Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003; 58(2):169-176.
151. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004; 89(1):71-75.
152. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 2003; 88(7):3196-3201.
153. Rodrigues EA, Caruana MP, Lahiri A, Nabarro JD, Jacobs HS, Raftery EB. Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. Br Heart J 1989; 62(3):185-194.
154. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, Meyer J. Arrhythmia profile in acromegaly. Eur Heart J 1992; 13(1):51-56.
155. Herrmann BL, Bruch C, Saller B, Ferdin S, Dagres N, Ose C, Erbel R, Mann K. Occurrence of ventricular late potentials in patients with active acromegaly. Clin Endocrinol (Oxf) 2001; 55(2):201-207.
156. Rizzoni D, Porteri E, Giustina A, De Ciuceis C, Sleiman I, Boari GE, Castellano M, Muiesan ML, Bonadonna S, Burattin A, Cerudelli B, Agabiti-Rosei E. Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension 2004; 43(3):561-565.
157. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25(1):102-152.
158. Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 2001; 34(11):1429-1433.
159. Pietrobelli DJ, Akopian M, Olivieri AO, Renauld A, Garrido D, Artese R, Feldstein CA. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens 2001; 15(9):601-605.
160. Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F. Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 2001; 4(4):259-262.
161. Donnelly PM, Grunstein RR, Peat JK, Woolcock AJ, Bye PT. Large lungs and growth hormone: an increased alveolar number? Eur Respir J 1995; 8(6):938-947.
162. Evans CC, Hipkin LJ, Murray GM. Pulmonary function in acromegaly. Thorax 1977; 32(3):322-327.
163. Iandelli I, Gorini M, Duranti R, Bassi F, Misuri G, Pacini F, Rosi E, Scano G. Respiratory muscle function and control of breathing in patients with acromegaly. Eur Respir J 1997; 10(5):977-982.
164. Dostalova S, Sonka K, Smahel Z, Weiss V, Marek J, Horinek D. Craniofacial abnormalities and their relevance for sleep apnoea syndrome aetiopathogenesis in acromegaly. Eur J Endocrinol 2001; 144(5):491-497.
165. Hochban W, Ehlenz K, Conradt R, Brandenburg U. Obstructive sleep apnoea in acromegaly: the role of craniofacial changes. Eur Respir J 1999; 14(1):196-202.
166. Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H, Mann K. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004; 151(3):309-315.
167. Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 2001; 55(4):477-483.
168. Saeki N, Isono S, Tanaka A, Nishino T, Higuchi Y, Uchino Y, Iuchi T, Murai H, Tatsuno I, Yasuda T, Yamaura A. Pre- and post-operative respiratory assessment of acromegalics with sleep apnea-bedside oximetric study for transsphenoidal approach. Endocr J 2000; 47 (suppl:S61-4):S61-S64.
169. Saeki N, Isono S, Nishino T, Iuchi T, Yamaura A. Sleep-disordered breathing in acromegalics-relation of hormonal levels and quantitative sleep study by means of bedside oximeter. Endocr J 1999; 46(4):585-590.
170. Clemmons DR. Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 2002; 5(3):181-183.
171. Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE, Alberti KG, Weeke J. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992; 74(5):1012-1019.
172. Foss MC. Peripheral glucose metabolism in healthy subjects and in endocrine diseases. Braz J Med Biol Res 1994; 27(4):959-979.
173. Foss MC, Saad MJ, Moreira AC. Peripheral muscle glucose and potassium transport in acromegaly. Horm Metab Res 1993; 25(1):45-47.
174. Foss MC, Saad MJ, Paccola GM, Paula FJ, Piccinato CE, Moreira AC. Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab 1991; 72(5):1048-1053.
175. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003; 149(6):521-527.
176. Renehan AG, O’Connell J, O’Halloran D, Shanahan F, Potten CS, O’dwyer ST, Shalet SM. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 2003; 35(11-12):712-725.
177. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83(8):2730-2734.
178. Delhougne B, Deneux C, Abs R, Chanson P, Fierens H, Laurent-Puig P, Duysburgh I, Stevenaert A, Tabarin A, Delwaide J, Schaison G, Belaiche J, Beckers A. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995; 80(11):3223-3226.
179. Renehan AG, Shalet SM. Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab 2002; 87(4):1909.
180. Jenkins PJ, Frajese V, Jones AM, Camacho-Hubner C, Lowe DG, Fairclough PD, Chew SL, Grossman AB, Monson JP, Besser GM. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000; 85(9):3218-3221.
181. Lieberman SA, Bjorkengren AG, Hoffman AR. Rheumatologic and skeletal changes in acromegaly. Endocrinol Metab Clin North Am 1992; 21(3): 615-631.
182. Colao A, Marzullo P, Vallone G, Marino V, Annecchino M, Ferone D, De Brasi D, Scarpa R, Oriente P, Lombardi G. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 1998; 83(6):2121-2125.
183. Badia X, Webb SM, Prieto L, Lara N. Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2004; 2(1):13.
184. Webb SM, Prieto L, Badia X, Albareda M, Catala M, Gaztambide S, Lucas T, Paramo C, Pico A, Lucas A, Halperin I, Obiols G, Astorga R. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 2002; 57(2):251-258.
185. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 2004; 89(11):5369-5376.
186. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly; persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005; 90(5):2731-2739.
187. Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW. Long-term treatment outcome in acromegaly. Growth Horm IGF Res 2003; 13(4):185-192.
188. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf) 1987; 26(4):481-512.
189. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73(5):233-240.
190. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991; 151(8):1573-1578.
191. Matsuoka LY, Wortsman J, Kupchella CE, Eng A, Dietrich JE. Histochemical characterization of the cutaneous involvement of acromegaly. Arch Intern Med 1982; 142(10):1820-1823.
192. Quatresooz P, Hermanns-Le T, Ciccarelli A, Beckers A, Pierard GE. Tensegrity and type 1 dermal dendrocytes in acromegaly. Eur J Clin Invest 2005; 35(2):133-139.
193. Centurion SA, Schwartz RA. Cutaneous signs of acromegaly. Int J Dermatol 2002; 41(10):631-634.
194. Braham C, Betea D, Pierard-Franchimont C, Beckers A, Pierard GE. Skin tensile properties in patients treated for acromegaly. Dermatology 2002; 204(4):325-329.
195. Zangeneh F, Carpenter PC. Visual vignette. Cutis verticis gyrata (CVG) in acromegaly. Endocr Pract 2002; 8(6):475.
196. Kolawole TM, Al Orainy IA, Patel PJ, Fathuddin S. Cutis verticis gyrata: its computed tomographic demonstration in acromegaly. Eur J Radiol 1998; 27(2):145-148.
197. O’Reilly FM, Sliney I, O’Loughlin S. Acromegaly and cutis verticis gyrata. J R Soc Med 1997; 90(2):79.
198. Hasan W, Cowen T, Barnett PS, Elliot E, Coskeran P, Bouloux PM. The sweating apparatus in growth hormone deficiency, following treatment with r-hGH and in acromegaly. Auton Neurosci 2001; 2089(1-2):100-109.
199. Burton JL, Libman LJ, Cunliffe WJ, Wilkinson R, Hall R, Shuster S. Sebum excretion in acromegaly. Br Med J 1972; 1(797):406-408.
200. Sneppen SB, Main KM, Juul A, Pedersen LM, Kristensen LO, Skakkebaek NE, Feldt-Rasmussen U. Sweat secretion rates in growth hormone disorders. Clin Endocrinol (Oxf) 2000; 53(5):601-608.
201. Feingold KR, Elias PM. Endocrine-skin interactions. Cutaneous manifestations of pituitary disease, thyroid disease, calcium disorders, and diabetes. J Am Acad Dermatol 1987; 17(6):921-940.
202. Leavitt J, Klein I, Kendricks F, Gavaler J, Van Thiel DH. Skin tags: a cutaneous marker for colonic polyps. Ann Intern Med 1983; 98(6):928-930.
203. Brown J, Winkelmann RK, Randall RV. Acanthosis nigricans and pituitary tumors. Report of eight cases. JAMA 1966; 198(6):619-623.
204. Scarpa R, De Brasi D, Pivonello R, Marzullo P, Manguso F, Sodano A, Oriente P, Lombardi G, Colao A. Acromegalic axial arthropathy: a clinical case-control study. J Clin Endocrinol Metab 2004; 89(2):598-603.
205. Podgorski M, Robinson B, Weissberger A, Stiel J, Wang S, Brooks PM. Articular manifestations of acromegaly. Aust N Z J Med 1988; 18(1):28-35.
206. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25(1):102-152.
207. Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F. Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 2001; 4(4):259-262.
208. Williams RG, Richards SH, Mills RG, Eccles R. Voice changes in acromegaly. Laryngoscope 1994; 104(4):484-487.
209. Smith M, Hirsch NP. Pituitary disease and anaesthesia. Br J Anaesth 2000; 85(1):3-14.
210. Hakala P, Randell T, Valli H. Laryngoscopy and fibreoptic intubation in acromegalic patients. Br J Anaesth 1998; 80(3):345-347.
211. Evans CC, Hipkin LJ, Murray GM. Pulmonary function in acromegaly. Thorax 1977; 32(3):322-327.
212. Donnelly PM, Grunstein RR, Peat JK, Woolcock AJ, Bye PT. Large lungs and growth hormone: an increased alveolar number? Eur Respir J 1995; 8(6):938-947.
213. Garcia-Rio F, Pino JM, Diez JJ, Ruiz A, Villasante C, Villamor J. Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion. Am J Respir Crit Care Med 2001; 164(5):852-857.
214. Iandelli I, Gorini M, Duranti R, Bassi F, Misuri G, Pacini F, Rosi E, Scano G. Respiratory muscle function and control of breathing in patients with acromegaly. Eur Respir J 1997; 10(5):977-982.
215. Trotman-Dickenson B, Weetman AP, Hughes JM. Upper airflow obstruction and pulmonary function in acromegaly: relationship to disease activity. Q J Med 1991; 79(290):527-538.
216. Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 2003; 24(3):272-277.
217. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004; 89(1): 71-75.
218. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 2003; 88(7):3196-3201.
219. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, Meyer J. Arrhythmia profile in acromegaly. Eur Heart J 1992; 13(1):51-56.
220. Jenkins PJ, Sohaib SA, Akker S, Phillips RR, Spillane K, Wass JA, Monson JP, Grossman AB, Besser GM, Reznek RH. The pathology of median neuropathy in acromegaly. Ann Intern Med 2000; 133(3):197-201.
221. Jamal GA, Kerr DJ, McLellan AR, Weir AI, Davies DL. Generalised peripheral nerve dysfunction in acromegaly: a study by conventional and novel neurophysiological techniques. J Neurol Neurosurg Psychiatry 1987; 50(7):886-894.
222. Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao AM, Lombardi G, Baldelli R, Camanni F, Liuzzi A. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 2002; 25(3):240-245.
223. Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, Hayden DL, Wright ME, Woodburn CJ, Klibanski A. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 2001; 54(2):183-188.
224. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004; 151(4):439-446.
225. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000; 85(10):3779-3785.
226. Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 2002; 13(5):395-400.
227. Renehan AG, O’Connell J, O’Halloran D, Shanahan F, Potten CS, O’dwyer ST, Shalet SM. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 2003; 35(11-12):712-725.
228. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 2003; 6(4):175-180.
229. Levitt NS, Ratanjee BD, Abrahamson MJ. Do “so-called” normal growth hormone concentrations (2-5 micrograms/L) indicate cure in acromegaly? Horm Metab Res 1995; 27(4):185-188.
230. Dimaraki EV, Jaffe CA, Demott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002; 87(8):3537-3542.
231. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988; 67(1):69-73.
232. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301(21):1138-1142.
233. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 2004; 89(7):3099-3102.
234. Daughaday WH, Starkey RH, Saltman S, Gavin JR III, Mills-Dunlap B, Heath-Monnig E. Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH. J Clin Endocrinol Metab 1987; 65(4):617-623.
235. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003; 88(10):4759-4767.
236. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998; 83(11):3808-3816.
237. Marro B, Zouaoui A, Sahel M, Crozat N, Gerber S, Sourour N, Sag K, Marsault C. MRI of pituitary adenomas in acromegaly. Neuroradiology 1997; 39(6):394-399.
238. Lundin P, Nyman R, Burman P, Lundberg PO, Muhr C. MRI of pituitary macroadenomas with reference to hormonal activity. Neuroradiology 1992; 34(1):43-51.
239. Vezina JL, Hardy J, Yamashita M. Microadenomas hypersecreting pituitary adenomas. Arq Neuropsiquiatr 1975; 33(2):119-127.
240. Bourdelot A, Coste J, Hazebroucq V, Gaillard S, Cazabat L, Bertagna X, Bertherat J. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. Eur J Endocrinol 2004; 150(6):763-771.
241. Athanassiadi K, Exarchos D, Tsagarakis S, Bellenis I. Acromegaly caused by ectopic growth hormone-releasing hormone secretion by a carcinoid bronchial tumor: a rare entity. J Thorac Cardiovasc Surg 2004; 128(4):631-632.
242. Osella G, Orlandi F, Caraci P, Ventura M, Deandreis D, Papotti M, Bongiovanni M, Angeli A, Terzolo M. Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. J Endocrinol Invest 2003; 26(2):163-169.
243. Lorcy Y, Perdu S, Sevray B, Cohen R. [Acromegaly due to ectopic GH RH secretion by a bronchial carcinoid tumor: a case report]. Ann Endocrinol (Paris) 2002; 63(6 pt 1):536-539.
244. Boix E, Pico A, Pinedo R, Aranda I, Kovacs K. Ectopic growth hormonereleasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxf) 2002; 57(1):131-134.
245. Doga M, Bonadonna S, Burattin A, Giustina A. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Ann Oncol 2001; 12(suppl 2):S89-S94.
246. Ezzat S, Ezrin C, Yamashita S, Melmed S. Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor. Cancer 1993; 71(1):66-70.
247. Melmed S, Ziel FH, Braunstein GD, Downs T, Frohman LA. Medical management of acromegaly due to ectopic production of growth hormonereleasing hormone by a carcinoid tumor. J Clin Endocrinol Metab 1988; 67(2):395-399.
248. Melmed S, Ezrin C, Kovacs K, Goodman RS, Frohman LA. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med 1985; 312(1):9-17.
249. Mitsuya K, Nakasu Y, Nioka H, Nakasu S. Ectopic growth hormonereleasing adenoma in the cavernous sinus-case report. Neurol Med Chir (Tokyo) 2004; 44(7):380-385.
250. Morel O, Giraud P, Bernier MO, Le Jeune JJ, Rohmer V, Jallet P. Ectopic acromegaly: localization of the pituitary growth hormone-releasing hormone producing tumor by In-111 pentetreotide scintigraphy and report of two cases. Clin Nucl Med 2004; 29(12):841-843.
251. Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111 In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med 2003; 44(8):1315-1321.
252. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. QJM 1999; 92(12):741-745.
253. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1999; 50(5):561-567.
254. Couldwell WT, Weiss MH, Rabb C, Liu JK, Apfelbaum RI, Fukushima T. Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: surgical experience in 105 cases. Neurosurgery 2004; 55(3):539-547.
255. Liu JK, Weiss MH, Couldwell WT. Surgical approaches to pituitary tumors. Neurosurg Clin N Am 2003; 14(1):93-107.
256. Sabit I, Schaefer SD, Couldwell WT. Modified infratemporal fossa approach via lateral transantral maxillotomy: a microsurgical model. Surg Neurol 2002; 58(1):21-31.
257. Karci B, Oner K, Gunhan O, Ovul I, Bilgen C. Nasomaxillary osteotomy in lesions of the central compartment of the middle cranial base. Rhinology 2001; 39(3):160-165.
258. Couldwell WT. Transsphenoidal and transcranial surgery for pituitary adenomas. J Neurooncol 2004; 69(1-3):237-256.
259. Colao A, Ferone D, Cappabianca P, Del Basso de Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997; 82(10):3308-3314.
260. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79(5):1416-1423.
261. Stevenaert A, Beckers A. Presurgical Octreotide: treatment in acromegaly. Metabolism 1996; 45(8) (suppl):72-74.
262. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67(5):1040-1048.
263. Kristof RA, Stoffel-Wagner B, Klingmuller D, Schramm J. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 1999; 141(4):399-405.
264. Lucas-Morante T, Garcia-Uria J, Estrada J, Saucedo G, Cabello A, Alcaniz J, Barcelo B. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 1994; 81(1):10-14.
265. Teasdale GM, Hay ID, Beasttall GH, McCruden DC, Thomson JA, Davies DL, Grossart KW, Ratcliffe JG. Cryosurgery or microsurgery in the management of acromegaly. JAMA 1982; 247(9):1289-1291.
266. Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg 1988; 68(6):854-867.
267. Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg 1993; 78(2):205-215.
268. Davis DH, Laws ER Jr, Ilstrup DM, Speed JK, Caruso M, Shaw EG, Abboud CF, Scheithauer BW, Root LM, Schleck C. Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg 1993; 79(1):70-75.
269. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21(3):669-692.
270. Grisoli F, Leclercq T, Jaquet P, Guibout M, Winteler JP, Hassoun J, Vincentelli F. Transsphenoidal surgery for acromegaly-long-term results in 100 patients. Surg Neurol 1985; 23(5):513-519.
271. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JA. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 1996; 45(4):407-413.
272. Fahlbusch R, Honegger J, Buchfelder M. Evidence supporting surgery as treatment of choice for acromegaly. J Endocrinol 1997; 155(suppl 1):S53-S55.
273. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83(10):3419-3426.
274. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998; 89(3):353-358.
275. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 2003; 88(8): 3567-3572.
276. Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000; 85(12):4596-4602.
277. Takahashi JA, Shimatsu A, Nakao K, Hashimoto N. Early postoperative indicators of late outcome in acromegalic patients. Clin Endocrinol (Oxf) 2004; 60(3):366-374.
278. Krieger MD, Couldwell WT, Weiss MH. Assessment of long-term remission of acromegaly following surgery. J Neurosurg 2003; 98(4):719-724.
279. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GHsecreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001; 86(9):4072-4077.
280. Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 2003; 10(4):611-619.
281. Esposito V, Santoro A, Minniti G, Salvati M, Innocenzi G, Lanzetta G, Cantore G. Transsphenoidal adenomectomy for GH-, PRL-and ACTHsecreting pituitary tumours: outcome analysis in a series of 125 patients. Neurol Sci 2004; 25(5):251-256.
282. Shimon I, Cohen ZR, Ram Z, Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001; 48(6):1239-1243.
283. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM, Grossman AB. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001; 86(4):1645-1652.
284. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER. Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) 2005; 10.1007/s00701-004-0466-2.
285. Bourdelot A, Coste J, Hazebroucq V, Gaillard S, Cazabat L, Bertagna X, Bertherat J. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. Eur J Endocrinol 2004; 150(6):763-771.
286. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998; 83(10):3411-3418.
287. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003; 58(1):86-91.
288. Long H, Beauregard H, Somma M, Comtois R, Serri O, Hardy J. Surgical outcome after repeated transsphenoidal surgery in acromegaly. J Neurosurg 1996; 85(2):239-247.
289. Kurosaki M, Luedecke DK, Abe T. Effectiveness of secondary transnasal surgery in GH-secreting pituitary macroadenomas. Endocr J 2003; 50(5): 635-642.
290. Nomikos P, Ladar C, Fahlbusch R, Buchfelder M. Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas-a study on 721 patients. Acta Neurochir (Wien) 2004; 146(1):27-35.
291. Inder WJ, Espiner EA, MacFarlane MR. Outcome from surgical management of secretory pituitary adenomas in Christchurch, New Zealand. Intern Med J 2003; 33(4):168-173.
292. van Lindert E, Hey O, Boecher-Schwarz H, Perneczky A. Treatment results of acromegaly as analyzed by different criteria. Acta Neurochir (Wien) 1997; 139(10):905-912.
293. Brazeau P, Guillemin R. Editorial: Somatostatin: newcomer from the hypothalamus. N Engl J Med 1974; 290(17):963-964.
294. Hall R, Besser GM, Schally AV, Coy DH, Evered D, Goldie DJ, Kastin AJ, McNeilly AS, Mortimer CH, Phenekos C, Tunbridge WM, Weightman D. Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet 1973; 2(7829):581-584.
295. Evered DC, Gomez-Pan A, Tunbridge WM, Hall R, Lind T, Besser GM, Mortimer CH, Thorner MO, Schally AV, Kastin AJ, Coy DH. Letter: Analogues of growth-hormone release-inhibiting hormone. Lancet 1975; 1(7918):1250.
296. Wajchenberg BL, Cesar FP, Leme CE, Borghi VC, Souza VC, Souza IT, Neto DG, Germek OA, Coy DH, Comaru-Schally AM. Dissociated effects of somatostatin analogs on arginine-induced insulin, glucagon and growth hormone release in acromegalic patients. Horm Metab Res 1983; 15(10):471-474.
297. Heron I, Thomas F, Dero M, Poutrain JR, Henane S, Catus F, Kuhn JM. [Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog]. Presse Med 1993; 22(11):526-531.
298. Reubi JC, Kvols L, Krenning E, Lamberts SW. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990; 39(9) (suppl 2):78-81.
299. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, Del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985; 19:313(25):1576-1580.
300. Lamberts SW, Oosterom R, Neufeld M, Del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60(6):1161-1165.
301. Horikawa R, Takano K, Hizuka N, Asakawa K, Shibasaki T, Masuda A, Shizume K. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly. Endocrinol Jpn 1986; 33(6):743-749.
302. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991; 151(8):1573-1578.
303. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab 1990; 71(2):391-397.
304. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992; 117(9): 711-718.
305. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 1995; 80(9):2768-2775.
306. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, Jervell J. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995; 80(12):3601-3607.
307. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot longacting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995; 80(11):3267-3272.
308. Grass P, Marbach P, Bruns C, Lancranjan I. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996; 45(8) (suppl 1):27-30.
309. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2004; 61(2):224-231.
310. Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79(1):145-151.
311. Soule S, Conway G, Hatfield A, Jacobs H. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicentre study. J Clin Endocrinol Metab 1996; 81(12): 4502-4503.
312. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano DG. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 1997; 27(4):277-284.
313. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002; 87(1):99-104.
314. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 2004; 60(6):734-740.
315. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87(7):3013-3018.
316. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 2004; 51(2): 227-236.
317. Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003; 58(4):387-399.
318. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83(9): 3034-3040.
319. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005; 152(1):61-66.
320. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999; 141(3):267-271.
321. Kendall-Taylor P, Miller M, Gebbie J, Turner S, al Maskari M. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 2000; 3(2):61-65.
322. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jimenez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000; 53(5):577-586.
323. Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004; 151(3):317-324.
324. van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frolich M, Smit JW, Corssmit EP, Roelfsema F, Pereira AM. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004; 150(4):489-495.
325. Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA, James RA. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004; 150(4):473-480.
326. Levy MJ, Bejon P, Barakat M, Goadsby PJ, Meeran K. Acromegaly: a unique human headache model. Headache 2003; 43(7):794-797.
327. Donangelo I, Rodacki M, Peixoto MC, Vaisman M, Caldas NR, Gadelha MR. Dependency and analgesia related to treatment with subcutaneous octreotide in patients with growth hormone-secreting tumors. Endocr Pract 2004; 10(2):107-111.
328. Sicolo N, Martini C, Ferla S, Roggenkamp J, Vettor R, De Palo C, Federspil G. [Analgesic effect of Sandostatin (SMS 201-995) in acromegaly headache]. Minerva Endocrinol 1990; 15(1):37-42.
329. Paunovic VR, Popovic V. The development of dependence to an octapeptide somatostatin analog: contribution to the study of somatostatin analgesia. Biol Psychiatry 1989; 26(1):97-101.
330. Stevenaert A, Harris AG, Kovacs K, Beckers A. Presurgical octreotide treatment in acromegaly. Metabolism 1992; 41(9) (suppl 2):51-58.
331. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphological variants of growth hormoneproducing pituitary adenomas to octreotide. Eur J Endocrinol 1995; 133(6): 686-690.
332. Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 1994; 79(1):113-118.
333. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F, Giovanelli M. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001; 86(11):5194-5200.
334. Bevan JS. The anti-turmoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005; 90(3):1856-1863.
335. Barakat S, Melmed S. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide. Arch Intern Med 1989; 149(6):1443-1445.
336. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995; 133(4):430-439.
337. Lundin P, Eden Engstrom B, Karlsson FA, Burman P. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. AJNR Am J Neuroradiol 1997; 18(4):765-772.
338. Ben Shlomo A, Melmed S. Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 2003; 88(3):963-968.
339. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334(4):246-254.
340. Catnach SM, Anderson JV, Fairclough PD, Trembath RC, Wilson PA, Parker E, Besser GM, Wass JA. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly. Gut 1993; 34(2):270-273.
341. Catnach SM, Wass JA, Anderson JV, Besser M, Fairclough P, Hussaini H, Dowling H. Gall stones induced by octreotide. BMJ 1992; 305(6848):313.
342. Schmidt K, Leuschner M, Harris AG, Althoff PH, Jacobi V, Jungmann E, Schumm-Draeger PM, Rau H, Braulke C, Usadel KH. Gallstones in acromegalic patients undergoing different treatment regimens. Clin Investig 1992; 70(7):556-559.
343. Dowling RH. Review: pathogenesis of gallstones. Aliment Pharmacol Ther 2000; 14(suppl 2):39-47.
344. Veysey MJ, Thomas LA, Mallet AI, Jenkins PJ, Besser GM, Wass JA, Murphy GM, Dowling RH. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Gut 1999; 44(5):675-681.
345. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003; 88(7):3090-3098.
346. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994; 130(6):581-586.
347. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992; 117(9):719-726.
348. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000; 85(9):3132-3140.
349. Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Monaghan M, Barr S, Harris PE. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary 2003; 6(1):11-18.
350. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulinlike growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001; 86(4):1551-1557.
351. Tachibana H, Yamaguchi H, Abe S, Sato T, Inoue S, Abe S, Yamaki M, Kubota I. Improvement of ventricular arrhythmia by octreotide treatment in acromegalic cardiomyopathy. Jpn Heart J 2003; 44(6):1027-1031.
352. Suyama K, Uchida D, Tanaka T, Saito J, Noguchi Y, Nakamura S, Tatsuno I, Saito Y, Saeki N. Octreotide improved ventricular arrhythmia in an acromegalic patient. Endocr J 2000; 47 (suppl):S73-S75.
353. Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, Birman P, Harris AG, Lubetzki J. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990; 113(12):921-925.
354. Otsuka F, Mizobuchi S, Ogura T, Sato K, Yokoyama M, Makino H. Longterm effects of octreotide on pituitary gigantism: its analgesic action on cluster headache. Endocr J 2004; 51(5):449-452.
355. Schmidt K, Althoff PH, Harris AG, Prestele H, Schumm-Draeger PM, Usadel KH. Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up. Pain 1993; 53(2):223-227.
356. Pascual J, Freijanes J, Berciano J, Pesquera C. Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Case report. Pain 1991; 47(3):341-344.
357. Popovic V, Paunovic VR, Micic D, Nesovic M, Kendereski A, Djordjevic P, Manojlovic D, Micic J. The analgesic effect and development of dependency to somatostatin analogue (octreotide) in headache associated with acromegaly. Horm Metab Res 1988; 20(4):250-251.
358. Williams G, Ball JA, Lawson RA, Joplin GF, Bloom SR, Maskill MR. Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours. Br Med J (Clin Res Ed) 1987; 295(6592):247-248.
359. Colao A, Cannavo S, Marzullo P, Pivonello R, Squadrito S, Vallone G, Almoto B, Bichisao E, Trimarchi F, Lombardi G. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol 2003; 148(1):31-38.
360. Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H, Mann K. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004; 151(3):309-315.
361. Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 2001; 55(4):477-483.
362. Chanson P, Timsit J, Benoit O, Augendre B, Moulonguet M, Guillausseau PG, Warnet A, Lubetzki J. Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995. Lancet 1986; 1(8492):1270-1271.
363. Leibowitz G, Shapiro MS, Salameh M, Glaser B. Improvement of sleep apnoea due to acromegaly during short-term treatment with octreotide. J Intern Med 1994; 236(2):231-235.
364. Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994; 121(7):478-483.
365. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992; 255(5042):306-312.
366. Kopchick JJ. Discovery and development of a new class of drugs: GH antagonists. J Endocrinol Invest 2003; 26(suppl 10):16-26.
367. USAN Council. List No.428. New names. Pegvisomant. Clin Pharmacol Ther 2000; 68(1):106.
368. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 2001; 86(4):1716-1723.
369. Goffin V, Bernichtein S, Carriere O, Bennett WF, Kopchick JJ, Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999; 140(8):3853-3856.
370. Maamra M, Kopchick JJ, Strasburger CJ, Ross RJ. Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. J Clin Endocrinol Metab 2004; 89(9):4532-4537.
371. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 1999; 84(6):2098-2103.
372. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358(9295):1754-1759.
373. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342(16):1171-1177.
374. Muller AF, Janssen JA, Lamberts SW, Bidlingmaier M, Strasburger CJ, Hofland L, van der Lely AJ. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion. Clin Endocrinol (Oxf) 2001; 55(4):461-467.
375. Parkinson C, Flyvbjerg A, Trainer PJ. High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization. Growth Horm IGF Res 2004; 14(1):59-65.
376. Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM, Trainer PJ. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol 2001; 145(4):451-456.
377. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000; 52(5):549-555.
378. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25(1):102-152.
379. Jaffrain-Rea ML, Minniti G, Moroni C, Esposito V, Ferretti E, Santoro A, Infusino T, Tamburrano G, Cantore G, Cassone R. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 2003; 148(2):193-201.
380. Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P, Terzolo M, Correra M, Ghiggi MR, Ferretti E, Angeli A, Sicolo N, Trischitta V, Liuzzi A, Cassone R, Tamburrano G. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) 2001; 54(2):189-195.
381. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000; 85(10):3779-3785.
382. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994; 130(6):581-586.
383. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 2002; 87(4):1797-1804.
384. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003; 149(6):521-527.
385. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf) 1987; 26(4):481-512.
386. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73(5):233-240.
387. Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marin F, Lucas T. Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int 1993; 52(6):419-421.
388. Kotzmann H, Bernecker P, Hubsch P, Pietschmann P, Woloszczuk W, Svoboda T, Geyer G, Luger A. Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 1993; 8(4): 459-465.
389. Terzolo M, Piovesan A, Osella G, Pia A, Reimondo G, Pozzi C, Raucci C, Torta M, Paccotti P, Angeli A. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment. Calcif Tissue Int 1993; 52(3):188-191.
390. Lieberman SA, Bjorkengren AG, Hoffman AR. Rheumatologic and skeletal changes in acromegaly. Endocrinol Metab Clin North Am 1992; 21(3): 615-631.
391. Ueland T, Ebbesen EN, Thomsen JS, Mosekilde L, Brixen K, Flyvbjerg A, Bollerslev J. Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Invest 2002; 32(2):122-128.
392. Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D, Klibanski A. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol (Oxf) 2002; 57(3):385-390.
393. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 2003; 88(12):5650-5655.
394. Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J, Mikulski E. Serum leptin levels in acromegaly-a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 2002; 8(10):CR685-CR689.
395. Damjanovic SS, Petakov MS, Raicevic S, Micic D, Marinkovic J, Dieguez C, Casanueva FF, Popovic V. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 2000; 85(1):147-154.
396. Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T. Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 1998; 83(10):3476-3479.
397. Silha JV, Krsek M, Hana V, Marek J, Jezkova J, Weiss V, Murphy LJ. Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol (Oxf) 2003; 58(6):736-742.
398. Adan L, Trivin C, Sainte-Rose C, Zucker JM, Hartmann O, Brauner R. GH deficiency caused by cranial irradiation during childhood: factors and markers in young adults. J Clin Endocrinol Metab 2001; 86(11):5245-5251.
399. Jorgensen JO, Vahl N, Dall R, Christiansen JS. Resting metabolic rate in healthy adults: relation to growth hormone status and leptin levels. Metabolism 1998; 47(9):1134-1139.
400. Tan KC, Tso AW, Lam KS. Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 2001; 54(1):31-35.
401. Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 2003; 59(2):168-174.
402. Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM, Monson JP. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 2001; 86(7):2989-2992.
403. van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001; 86(2):478-481.
404. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003; 88(10):4759-4767.
405. Sachdev Y, Gomez-Pan A, Tunbridge WM, Duns A, Weightman DR, Hall R, Goolamali SK. Bromocriptine therapy in acromegaly. Lancet 1975; 2(7946):1164-1168.
406. Summers VK, Hipkin LJ, Diver MH, Davis JC. Treatment of acromegaly with bromocryptine. J Clin Endocrinol Metab 1975; 40(5):904-906.
407. Thorner MO, Chait A, Aitken M, Benker G, Bloom SR, Mortimer CH, Sanders P, Mason AS, Besser GM. Bromocriptine treatment of acromegaly. Br Med J 1975; 1(5953):299-303.
408. Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab 1974; 38(5):910-912.
409. Lloyd RV, Cano M, Chandler WF, Barkan AL, Horvath E, Kovacs K. Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization. Am J Pathol 1989; 134(3):605-613.
410. Lloyd RV, Anagnostou D, Cano M, Barkan AL, Chandler WF. Analysis of mammosomatotropic cells in normal and neoplastic human pituitary tissues by the reverse hemolytic plaque assay and immunocytochemistry. J Clin Endocrinol Metab 1988; 66(6):1103-1110.
411. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992; 21(3):713-735.
412. Liuzzi A, Chiodini PG, Oppizzi G, Botalla L, Verde G, De Stefano L, Colussi G, Graf KJ, Horowski R. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans. J Clin Endocrinol Metab 1978; 46(2):196-202.
413. Kendall-Taylor P, Upstill-Goddard G, Cook D. Longterm pergolide treatment of acromegaly. Clin Endocrinol (Oxf) 1983; 19(6):711-719.
414. Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clin Endocrinol (Oxf) 2001; 54(4):469-477.
415. Nickelsen T, Jungmann E, Althoff P, Schumm-Draeger PM, Usadel KH. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study. Arzneimittelforschung 1993; 43(4):421-425.
416. Oppizzi G, Liuzzi A, Chiodini P, Dallabonzana D, Spelta B, Silvestrini F, Borghi G, Tonon C. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. J Clin Endocrinol Metab 1984; 58(6):988-992.
417. Kleinberg DL, Boyd AE III, Wardlaw S, Frantz AG, George A, Bryan N, Hilal S, Greising J, Hamilton D, Seltzer T, Sommers CJ. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983; 309(12):704-709.
418. Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, Fortini P, Dubini A. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamineresponsive acromegalic patients. Clin Endocrinol (Oxf) 1988; 29(5):467-476.
419. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83(2):374-378.
420. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 1998; 139(5):516-521.
421. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004; 61(2):209-215.
422. Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999; 1(2):115-120.
423. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997; 82(2):518-523.
424. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD. Cabergoline therapy of growth hormone and growth hormone/prolactin secreting pituitary tumors. Pituitary 2004; 7(1):21-30.
425. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002; 87(12):5545-5552.
426. Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992; 21(3):693-712.
427. Wass JA. Radiotherapy in acromegaly: a protagonists viewpoint. Clin Endocrinol (Oxf) 2003; 58(2):128-131.
428. Barkan AL. Radiotherapy in acromegaly: the argument against. Clin Endocrinol (Oxf) 2003; 58(2):132-135.
429. Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005; 62(2):210-216.
430. Brada M, Rajan B, Traish D, Ashley S, Holmes-Sellors PJ, Nussey S, Uttley D. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993; 38(6):571-578.
431. Jalali R, Brada M, Perks JR, Warrington AP, Traish D, Burchell L, McNair H, Thomas DG, Robinson S, Johnston DG. Stereotactic conformal radiotherapy for pituitary adenomas: technique and preliminary experience. Clin Endocrinol (Oxf) 2000; 52(6):695-702.
432. Perks JR, Jalali R, Cosgrove VP, Adams EJ, Shepherd SF, Warrington AP, Brada M. Optimization of stereotactically-guided conformal treatment planning of sellar and parasellar tumors, based on normal brain dose volume histograms. Int J Radiat Oncol Biol Phys 1999; 45(2):507-513.
433. Milker-Zabel S, Zabel A, Huber P, Schlegel W, Wannenmacher M, Debus J. Stereotactic conformal radiotherapy in patients with growth hormone-secreting pituitary adenoma. Int J Radiat Oncol Biol Phys 2004; 59(4):1088-1096.
434. Laws ER, Sheehan JP, Sheehan JM, Jagnathan J, Jane JA Jr, Oskouian R. Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol 2004; 69(1-3):257-272.
435. Zhang N, Pan L, Wang EM, Dai JZ, Wang BJ, Cai PW. Radiosurgery for growth hormone-producing pituitary adenomas. J Neurosurg 2000; 93(suppl 3):6-9.
436. Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) 2002; 57(6):713-717.
437. Erfurth EM, Bulow B, Svahn-Tapper G, Norrving B, Odh K, Mikoczy Z, Bjork J, Hagmar L. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 2002; 87(11):4892-4899.
438. Jones A. Radiation oncogenesis in relation to the treatment of pituitary tumours. Clin Endocrinol (Oxf) 1991; 35(5):379-397.
439. Bliss P, Kerr GR, Gregor A. Incidence of second brain tumours after pituitary irradiation in Edinburgh 1962-1990. Clin Oncol (R Coll Radiol) 1994; 6(6):361-363.
440. Brada M, Ford D, Ashley S, Bliss JM, Crowley S, Mason M, Rajan B, Traish D. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 1992; 304(6838):1343-1346.
441. Tsang RW, Laperriere NJ, Simpson WJ, Brierley J, Panzarella T, Smyth HS. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 1993; 72(7):2227-2233.